Prediction of systemic exposure by food effect on a fixed‐dose combination of linagliptin and metformin extended‐release

Documenti analoghi

• Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
  di: Qian Ren, et al.
  Pubblicazione: (2024)
• A comparative study of the effects of imeglimin add‐on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low‐dose metformin ( MEGMI‐CGM study)
  di: Akihiro Takahashi, et al.
  Pubblicazione: (2024)
• Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
  di: So Ra Kim, et al.
  Pubblicazione: (2026)
• Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial
  di: Michaël J. B. van Baar, et al.
  Pubblicazione: (2025)
• Optimising the Therapeutic Window: A Systematic Review and Network Meta‐Analysis of Pregabalin Dosing Strategies for Painful Diabetic Neuropathy
  di: Doyun Kwon, et al.
  Pubblicazione: (2026)